Pyruvate Kinase M2 Regulates Apoptosis of Intestinal Epithelial Cells in Crohn’s Disease

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 393-404

  Tang, Qiyun ^a   Ji, Qianqian ^b   Xia, Weiwei ^b   Li, Liren ^b   Bai, Jian’an ^a   Ni, Runzhou ^b   Qin, Yongwei ^c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c NANTONG MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Crohn s disease; Intestinal epithelial cell; Pyruvate kinase M2

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; AUTACOID; CARRIER PROTEIN; MEMBRANE PROTEIN; PYRUVATE KINASE; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CASE CONTROL STUDY; CHEMICALLY INDUCED; COLON; CROHN DISEASE; DISEASE MODEL; ENZYMOLOGY; EPITHELIUM CELL; FEMALE; GENETIC TRANSFECTION; GENETICS; HT 29 CELL LINE; HUMAN; INTESTINE MUCOSA; METABOLISM; MOUSE; PATHOLOGY; PROSPECTIVE STUDY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASE-CONTROL STUDIES; COLON; CROHN DISEASE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; HT29 CELLS; HUMANS; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PROSPECTIVE STUDIES; PYRUVATE KINASE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID HORMONES; TIME FACTORS; TRANSFECTION; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925029595     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3189-0     Document Type: Article

References (49)

1. Lichtenberger GS, Flavell RA, Alexopoulou L. Innate immunity and apoptosis in IBD. Inflamm Bowel Dis. 2004;10:S58–S62.
2. Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130:1039–1046.
3. Busch K, Ludvigsson JF, Ekstrom-Smedby K, Ekbom A, et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39:57–68.
4. Solberg IC, Vatn MH, Hoie O, Stray N, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438.
5. Zheng JJ, Shi XH, Zhu XS, Huangfu Z, Guo ZR. A comparative study of incidence and prevalence of Crohn’s disease in mainland China in different periods. Zhonghua Nei Ke Za Zhi. 2011;50:597–600.
6. Kim MJ, Choe YH. Change in the treatment strategy for pediatric Crohn’s disease. Korean J Pediatr. 2010;53:830–833.
7. Keita AV, Soderholm JD. Barrier dysfunction and bacterial uptake in the follicle-associated epithelium of ileal Crohn’s disease. Ann N Y Acad Sci. 2012;1258:125–134.
8. Ruemmele FM, Seidman EG, Lentze MJ. Regulation of intestinal epithelial cell apoptosis and the pathogenesis of inflammatory bowel disorders. J Pediatr Gastroenterol Nutr. 2002;34:254–260.
9. Scharl M, McCole DF, Weber A, Vavricka SR, et al. Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut. 2011;60:189–197.
10. Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, et al. Increased enterocyte apoptosis in inflamed areas of Crohn’s disease. Dis Colon Rectum. 2003;46:1498–1507.
11. Schulzke JD, Bojarski C, Zeissig S, Heller F, et al. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci. 2006;1072:288–299.
12. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, et al. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS ONE. 2013;8:e57610.
13. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–308.
14. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43:969–980.
15. Harris I, McCracken S, Mak TW. PKM2: a gatekeeper between growth and survival. Cell Res. 2012;22:447–449.
16. Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol. 2013;2013:242513.
17. Day AS, Judd T, Lemberg DA, Leach ST. Fecal M2-PK in children with Crohn’s disease: a preliminary report. Dig Dis Sci. 2012;57:2166–2170.
18. Jeffery J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Inflamm Bowel Dis. 2009;15:1630–1634.
19. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012;209:217–224.
20. Guo W, Zhang Y, Chen T, Wang Y, et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol. 2011;137:65–72.
21. Kwon OH, Kang TW, Kim JH, Kim M, et al. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun. 2012;423:38–44.
22. Michels J, Kepp O, Senovilla L, Lissa D, et al. Functions of BCL-X L at the Interface between Cell Death and Metabolism. Int J Cell Biol. 2013;2013:705294.
23. Hollenbach E, Vieth M, Roessner A, Neumann M, et al. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem. 2005;280:14981–14988.
24. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281–1290.
25. Tao T, Cheng C, Ji Y, Xu G, et al. Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-kappaB activation. Mol Biol Cell. 2012;23:2635–2644.
26. Zhou CF, Li XB, Sun H, Zhang B, et al. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life. 2012;64:775–782.
27. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344–1367.
28. Qiu W, Wu B, Wang X, Buchanan ME, et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest. 2011;121:1722–1732.
29. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13:7254–7263.
30. Wang J, Fu YX. Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev. 2005;204:144–155.
31. Yan F, John SK, Polk DB. Kinase suppressor of Ras determines survival of intestinal epithelial cells exposed to tumor necrosis factor. Cancer Res. 2001;61:8668–8675.
32. Stetak A, Veress R, Ovadi J, Csermely P, et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007;67:1602–1608.
33. Al-Sadi R, Guo S, Dokladny K, Smith MA, et al. Mechanism of interleukin-1beta induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res. 2012;32:474–484.
34. Alecu L, Ursut B, Obrocea F, Marinescu E, et al. The surgical treatment for Crohn’s disease. Chirurgia (Bucur). 2013;108:463–467.
35. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn’s disease changed during the last four decades? Aliment Pharmacol Ther. 2004;20:483–496.
36. Edelblum KL, Yan F, Yamaoka T, Polk DB. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm Bowel Dis. 2006;12:413–424.
37. Kefas B, Comeau L, Erdle N, Montgomery E, et al. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010;12:1102–1112.
38. Shi HS, Li D, Zhang J, Wang YS, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 2010;101:1447–1453.
39. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.
40. Lee SY, Debnath T, Kim SK, Lim BO. Anti-cancer effect and apoptosis induction of cordycepin through DR3 pathway in the human colonic cancer cell HT-29. Food Chem Toxicol. 2013;60:439–447.
41. Gao X, Wang H, Yang JJ, Chen J, et al. Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. J Biol Chem. 2013;288:15971–15979.
42. Zhao Y, Altman BJ, Coloff JL, Herman CE, et al. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol. 2007;27:4328–4339.
43. Tarze A, Deniaud A, Le Bras M, Maillier E, et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene. 2007;26:2606–2620.
44. Loar P, Wahl H, Kshirsagar M, Gossner G, et al. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2010;202:e1–e8.
45. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299–310.
46. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 2013;155:397–409.
47. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6:297–305.
48. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005;40:1493–1494.
49. Czub E, Herzig KH, Szaflarska-Popawska A, Kiehne K, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147–1150.